Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RBC Capital ups price target on Hikma

(Sharecast News) - RBC Capital Markets has upped both forecasts and its price target for blue chip generics specialist Hikma Pharmaceuticals. The broker said Hikma had recently provided mid-term guidance that "reflects growing optimism about the Rx and injectables businesses".

It continued: "This adds to the positive outlook for the branded unit, communicated in late 2024. Overall, Hikma anticipates three-year revenue growth of 6% to 8% per annual, and core operating profit growth of 7% to 9% per annum."

RBC has therefore increased its 2027 forecasts for earnings before interest and tax by 9%, and the price target by 3%, to 2,635p.

It concluded: "With 27% upside, we reiterate our 'outperform' recommendation."

As at 1330 BST, shares in Hikma were largely flat at 2,078p.

Share this article

Related Sharecast Articles

Tandem Group on track to meet FY expectations
(Sharecast News) - Sports equipment company Tandem Group said on Tuesday that it remains on track to meet market expectations for the financial year ending 31 December.
Simplified Saga makes solid start to year
(Sharecast News) - Saga reported a solid start to its financial year on Tuesday, with trading for the first four months to 23 June in line with expectations across all divisions.
RBC Capital Markets starts On The Beach at 'outperform'
(Sharecast News) - RBC Capital Markets started coverage of On The Beach on Tuesday with an 'outperform' rating and 340p price target, sending shares in the online package holiday platform surging.
Google faces change to UK searches under regulator plan
(Sharecast News) - Google may have to make changes to its search engine in the UK and give users the option to try alternative services as the competition watchdog looks to tighten regulation of the tech giant.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.